Sanofi's Aubagio (teriflunomide) Receives EC's Approval as First Oral MS Therapy for 1L Treatment with Relapsing-Remitting Multiple Sclerosis in Children and Adolescents
Shots:
- The EC approval is based on a P-III TERIKIDS study evaluating Aubagioin vs PBO in 166 pediatric patients aged 10-17yrs. with RRMS across 22 countries globally- where a screening period (4wks.) is followed by a double-blind treatment period for ~96wks.
- The 1EPs is not significant with numerically a lower risk (-34%) of clinical relapse (75.3 vs 39.1wks.)- switches were more frequent (14% vs 26%). In the pre-specified sensitivity analysis- teriflunomide reduced the time to clinical relapse or switch due to high MRI activity by 43% (72.1 vs 37.0 wks.)
- Aubagio is approved in 80+ countries for RRMS with additional marketing applications under review by regulatory authorities globally
| Ref: GlobeNewswire | Image: Pharmaceutical Technology
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
